Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Awaiting decision

Provisional Schedule

Committee meeting:

13 January 2026

Project Team

Project lead

Jennifer Upton

Email enquiries

If you have any queries please email TACommA@nice.org.uk

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about topic prioritisation